On August 30, 2018 Personalis, Inc., a leading provider of advanced genomic sequencing and analytics to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies, reported that they are scheduled to present at the Immuno-Oncology Summit in Boston, MA on August 30, 2018 at 12:15 PM ET (Press release, Personalis, AUG 30, 2018, View Source [SID1234529174]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation, entitled "Overcoming the Obstacles of Neoantigen Detection for Cancer Vaccine Development," will discuss how the Personalis ACE ImmunoID Platform addresses the challenges associated with accurately identifying candidate neoantigens to enable the development of safe and efficacious personalized cancer vaccines. The presentation will be delivered by Kedar Hastak, PhD, Field Applications Scientist.

ACE ImmunoID is a universal immunogenomics platform, purpose-built for precision oncology applications, combining highly-sensitive exome and transcriptome sequencing with advanced analytics. The platform provides a multidimensional view of both the tumor and its microenvironment, and is the platform-of-choice for many industry-leading biopharma in the neoantigen-based cancer immunotherapy field.

On August 30, 2018 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), reported that John P. Butler, President and Chief Executive Officer, will participate in the following investor conferences (Press release, Akebia, AUG 30, 2018, View Source [SID1234529193]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on Thursday, September 6, 2018, at 1:45 p.m. Eastern Time, at the St. Regis New York Hotel.

The 16th Annual Morgan Stanley Global Healthcare Conference on Friday, September 14, 2018, at 10:30 a.m. Eastern Time, at the Grand Hyatt New York.

A live webcast of the presentations will be available on the company’s website at www.akebia.com. To access, please log onto the Akebia website at least 15 minutes prior to the webcasts to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Akebia’s website following the conferences.

On August 30, 2018 Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, reported that Stephen Yoder, President and Chief Executive Officer, will present at the 20th Annual Rodman & Renshaw Global Investment Conference on Wednesday, September 5th at 12:05PM EDT at the St. Regis New York Hotel in New York (Press release, Pieris Pharmaceuticals, AUG 30, 2018, https://ir.pieris.com/news/detail/599/pieris-pharmaceuticals-to-present-at-the-20th-annual-rodman-renshaw-global-investment-conference [SID1234529215]). A webcast of the Company’s presentation will be available at this link.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 29, 2018 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reported that the company is scheduled to participate in H.C. Wainwright 20th Annual Global Investment Conference in New York City (Press release, Ligand, AUG 29, 2018, View Source [SID1234529134]). Presentation takes place on Wednesday, September 5, 2018 at 12:30 p.m. Eastern time (9:30 a.m. Pacific time). John Higgins, CEO, and Matt Korenberg, CFO, will attend for Ligand.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on Ligand’s website at www.ligand.com. A replay of the presentation will be archived on the website for 30 days.

On August 29, 2018 Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, reported it will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC (Press release, Heat Biologics, AUG 29, 2018, https://ir.heatbio.com/news/detail/607/heat-biologics-to-present-at-the-20th-annual-rodman-renshaw-global-investment-conference-in-new-york-city [SID1234529118]). The conference is being held on September 4-6, 2018 at The St. Regis New York in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jeff Wolf, Founder and Chief Executive Officer of Heat Biologics, will provide an overview of the Company’s business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Event: 20th Annual Rodman & Renshaw Global Investment Conference

Date: Wednesday, September 5, 2018

Time: 4:40-5:05 PM (Eastern Time)

Location: Louis XVI B; The St. Regis New York

If you are unable to attend and would like to view the Company’s live webcast, please click on the following link (View Source).